
Full name:Prothena Corporation plc;
Full Address:Adelphi Plaza Upper George's Street Dún Laoghaire A96 T927 Ireland 353 1 236 2500 http://www.prothena.com;
Sector:Healthcare;
Industry:Biotechnology;
Market Car: 2.16B;

Description:
 Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, andcommercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion.It is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III andPhase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial fortreating Parkinsons disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib forthe treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinicaldevelopment. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd andHoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plcwas incorporated in 2012 and is headquartered in Dún Laoghaire, Ireland.;

Fiscal Year:2016;
Total Revenue:1055;
Net Revenue:-160108;
Total Assets:459976;

Fiscal Year:2015;
Total Revenue:1607;
Net Revenue:-80612;
Total Assets:385236;

Fiscal Year:2014;
Total Revenue:50854;
Net Revenue:-7150;
Total Assets:304116;


